Neurovascular Intervention

Overall, considerably more success has been achieved in reducing the thrombogenicity of bio-artificial surfaces than in controlling complement activation: For example, surfaces coated with different forms of heparin or PEG are associated with low or negligible activation of coagulation and subsequent platelet loss. Thus, there are numerous surfaces that have low thrombogenicity available that still bear substantial complement-activating capacity. Some of these materials will no doubt be a

This product is intended for general endovascular procedures, including the intravascular delivery of diagnostic agents (contrast media) and appropriate devices (coils, stents) within the neurovascular system. 

Tadalafil, which has the longest half-life among PDE-5 inhibitors, does not prevent endothelial apoptosis as much as nimodipine, but it still prevents smooth muscle cell proliferation in the tunica media, restores damaged endothelial integrity, increases cerebral blood flow, and is thought to have various neuroprotective functions through the PI3K/AKT/eNOS signaling pathway. We believe that more in-depth research on tadalafil in the future will prove the therapeutic potential of this drug for DCI.

This breakthrough medical device product is the first drug-eluting stent for the treatment of intracranial atherosclerotic stenosis in the history of the U.S. FDA, and it is also the first domestic neurointerventional device product to be recognized as a breakthrough medical device by the U.S. FDA.

AD is independently associated with an increased risk of stroke, especially in men, and there is a notable association with ischemic stroke. Moreover, the risk appears to be positively correlated with the severity of AD.

While clot composition does not significantly affect the success of First Pass Recanalization (FPR), it is significantly associated with the risk of intracranial hemorrhage. This underscores the potential clinical relevance of clot histology in predicting post-thrombectomy outcomes, beyond the well-established importance of FPR itself. Future studies with larger and more diverse patient cohorts are warranted to further elucidate these associations and optimize treatment strategies.

A novel study reveals that targeting a single protein’s aggregation can dramatically reduce brain injury after stroke, potentially transforming how acute ischemic strokes are treated.

This study estimated increases of hospital LOS and costs for patients with severe surgical bleeding complications in France. Hospitalisations longer than the average LOS across all DRGs indicated significant costs associated with severe post-surgical bleeding. Awareness of the clinical and economic consequences of severe post-surgical bleeding provides an important framework when evaluating blood conservation strategies.

Antiplatelet therapy is key to reducing local thrombotic complications and systemic ischaemic events among patients undergoing percutaneous coronary interventions (PCI), but it is inevitably associated with increased bleeding. The continuous refinement in stent technologies, together with the high incidence of ischaemic recurrences after PCI and the understanding of prognostic implications associated with bleeding, have led to a substantial evolution in antiplatelet treatment regimens over the past decades.

CD31 signaling promotes the switching of proinflammatory macrophages to the reparative phenotype and favors the healing of experimental dissected aortas. Treatment with a drug-suitable CD31 agonist may facilitate the clinical management of ADIM.

In past decades, the discovery of stem cells and byproducts has led to promising results in in vitro settings and pre-clinical studies. Extracellular vesicles (EVs) are nano-sized particles released from various cell types, for instance, mesenchymal stem cells (MSCs), with certain signaling biomolecules, growth factors, and cytokines involved in cell-to-cell communication. A great plethora of studies have pointed to the fact that EVs with specific cargo can distribute easily in different parts of the body, making them appropriate therapeutics under different pathological conditions. The current review articles aimed to highlight the neuroangiogenesis properties of MSC EVs in IS conditions. How and by which mechanisms MSC EVs can orchestrate the process of nervous system regeneration is at the center of debate.

AUCURA represents China’s first flow-diverting stent featuring both 0.017-inch system deliverability and an antithrombotic coating. The stent is woven from cobalt-chromium-platinum DFT wire with full-body radiopacity. Its superhydrophilic surface technology reduces contact angle to minimize plasma protein/platelet adhesion, significantly lowering the risk of stent thrombosis. By modifying aneurysm hemodynamics and promoting endothelial healing at the neck region, AUCURA enables effective treatment of intracranial aneurysms.

The AUCURA blood flow-diverter was officially approved by China's National Drug Administration (NMPA). This product is the first dense-mesh stent that can be transported by a 0.017" system, and with an antithrombotic eG NTMA coating, bringing a complete upgrade in the treatment of intracranial aneurysm.

Expanding care to stroke victims is one of medtech’s biggest opportunities, and startup Artedrone is developing a microrobot system that can navigate to blood clots for autonomous mechanical thrombectomies.

The findings demonstrate that heparin coated flow diverter stents are characterized by a lower thrombotic signature than bare metal flow diverter stents and raise the possibility of an additional therapeutic option to treat intracranial aneurysms.

Despite the continual progress in technology, thromboembolic complications still occur following endovascular treatment of cerebral aneurysms and remain the primary contributor to morbidity and mortality. Thus, coating the surfaces of blood-contacting flow diverters may reduce thrombus-related complications in clinical use. In this study, the hemocompatibility of different commercially available flow diverters Pipeline Flex Embolization Device with Shield Technology (Medtronic), the p64 MW HPC (Phenox), and the DERIVO 2heal (Acandis) was investigated using an in vitro blood circulation model.

While stroke treatment has dramatically changed in recent years, still around 795,000 people experience a new or recurrent stroke each year, and of all strokes 87% are ischaemic.1 A high variability in accessing stroke treatments exists across different countries or different regions within the same nation, even if at present guidelines are quite definitive in indicating endovenous thrombolysis and mechanical thrombectomy (MT) in selected cases as key treatment points. However, treatment indications are continuously evolving and so the vascular surgery world should be prepared to evolve accordingly.

Stryker notes that the Artix system builds on the success of Inari’s venous thrombectomy devices and is its inaugural entry into the arterial space. “Inari offers a comprehensive toolkit approach to arterial thrombectomy with an innovative, over-the-wire system that provides physicians with the flexibility to aspirate and/or mechanically extract a clot,” a press release reads.

The study assessed the working status of Norwegian patients with untreated unruptured intracranial aneurysms (UIAs) from 2008 to 2018. It found that these patients had significantly lower work participation pre- and post-diagnosis compared to the general population, highlighting potential psychological and health burdens.

Medtronic's Pipeline Vantage embolization device with Shield Technology is used to treat cerebral aneurysms. This endovascular interventional device is implanted into a blood vessel through a minimally invasive catheter to deliver the braided catheter to the aneurysm site to block blood flow.

Warfarin is the standard treatment for left ventricular thrombus. However, patients taking warfarin must undergo frequent blood tests to check that the time it takes for their blood to clot remains in a therapeutic range (an INR, International Normalized Ratio, of 2-3). Many other medications and foods can interact with warfarin, potentially increasing the patient's risk for ischemic and bleeding complications.

The intracranial aneurysm has a certain incidence in the general population, the fatality rate is high after rupture, and the safety and effectiveness of intravascular therapy have been confirmed by many trials, but the intravascular treatment of complex intracranial aneurysms is still facing challenges. The blood flow guidance device (FD) developed based on the hemodynamic research of intracranial aneurysm, changed the concept of intravascular treatment, and its principle is to reshape the local blood flow so that the aneurysm forms thrombosis in the aneurysm and thus block the aneurysm. However, the large-scale application of FD in clinical time is short, and its indications, perioperative period management, surgical operation techniques, and complication prevention and treatment are clinically controversial, and there are no relevant guidelines or consensus in China.

Microplastics are everywhere—in our water, food, and even the air we breathe. A new scientific review highlights a growing concern: microplastics and nanoplastics are accumulating in human brain tissue. Researchers are now investigating what this could mean for brain health and how we can reduce our exposure.